PPT-Tenofovir Alafenamide (TAF)

in a SingleTablet Regimen in Initial HIV1 Therapy Combined Primary Results of Studies GSUS2920104 and GSUS2920111 David Wohl 1 Anton Pozniak 2 Melanie Thompson 3 Edwin DeJesus. based . PrEP. technologies in women : . what do we currently know?. Linda-Gail Bekker . The Desmond Tutu HIV Centre. University of Cape Town.. Expanding HIV Prevention Options for Women.. The need for a female initiated, managed and controlled prevention methodology.. John J. . Faragon. , . PharmD. , BCPS, AAHIV-P. Albany Medical Center Hospital. NY/NJ AIDS Education and Training Center. When to Start. DHHS: Changing Criteria for Initiating ART. CD4+ Count, cells/mm. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, Frontier AETC ECHO. October 2015. ID Week Review 2015. 1) Switching from TDF to TAF. 2) Simplifying salvage therapy to E/C/F/TAF + DRV. School context. Mixed, 11-16 comprehensive, urban area of Llanelli. 900 pupils. 24.6% FSM. 48% cohort living in 20% most deprived areas in Wales . All Wales Core Data - family 9. In-school strategies. A.Dravid. 1. ,A.Sadre. 2. ,S.Dhande. 1. , A.Borkar. 1. ,M.Kulkarni. 1. ,M.Dravid. 3. 1. . Ruby hall clinic, Department of HIV Medicine, . Pune. , India. 2. Ruby hall clinic, Department of Nephrology, . of HIV. . Convenience, tolerability, simplicity. New & Investigational Agents. “Quad” Pill- . Stribild. Released by FDA 08-27-12. Tenofovir Emtricitabine Cobicistat Elvitegravir. “Booster”. GS-US-292-0109 Study. GS-US-311-1089 Study. . Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 (ITT, snapshot) ; non-inferiority if lower margin of a two-sided 95% CI for the difference = -10%, > 95% power. Navigating the New Treatment Landscape. Outline. Interpretation of HBV Serologic Tests. The Hepatitis B Virus. Goals of Therapy. When and What to Start: The Guidelines. New Treatment Options. Choosing Among Good Options. Heathland ingWoodland ingRoom ypeSundewHazelOrchidBirchGorseHollyBrackenAshHeatherOakMossBeech4/5 Bedded Pupil RoomSundewOrchidEXITSOUTHGorseBrackenHeatherMossEntranceLibraryAshHollyBirchHazelOakBeech STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ADONE Trial. Simplification to Efavirenz-Tenofovir DF-Emtricitabine . ADONE: Study Design. Source: . Airoldi. M, et al. Patient Prefer Adherence. 2010;4:115-25.. Study Design: ADONE Study . Background. FTC. Study 311-1089. Switching from TDF/FTC to TAF/. FTC. Study 311: Design. Source. : Gallant JE, et al. Lancet HIV. 2016;3:e158-65.. Switch to TAF/FTC*. . (n = 333). Continue TDF/FTC. (n = 330). *Patients on a pharmacokinetic booster (ritonavir) received tenofovir alafenamide-emtricitabine 10/200 mg. Study 112. Elvitegravir-Cobicistat-TAF-FTC in Renal Impairment. Study 112: . Design. Source: . Pozniak. A, et al. J . Acquir. Immune . Defic. . Syndr. . 2016;71:530-7.. Baseline ART*. (n = 242). Study Design: Study 112. . Disoproxil. . Fumarate. (TDF)-Based Regimen to a . Tenofovir. . Alafenamide. (TAF)-Based Regimen: Data in . Virologically. Suppressed Adults Through 48 Weeks of Treatment. Anthony Mills,. 1. .